Related Experiment Videos
Adjuvants to thrombolysis after acute myocardial infarction. Does adding antiplatelet agents, antithrombotics, or
V M Figueredo1, T M Amidon, C L Wolfe
1Department of Cardiology, University of California, San Francisco, Moffitt Hospital 94143-0124.
Insights
Thrombolytic therapy significantly lowers mortality in acute myocardial infarction (MI). Aspirin is a proven adjuvant, while the roles of other antiplatelet agents and heparin require further investigation for optimal MI treatment.
Area of Science:
- Cardiology
- Internal Medicine
Background:
- Acute myocardial infarction (MI) treatment aims to reduce mortality and improve cardiac function.
- Thrombolytic therapy is a cornerstone of acute MI management.
- Adjuvant therapies are explored to enhance outcomes.
Purpose of the Study:
- To review the efficacy of thrombolytic therapy in acute myocardial infarction.
- To evaluate the role of adjuvant therapies, including antiplatelet agents and anticoagulants.
- To assess the current and potential roles of angioplasty in acute MI management.
Main Methods:
- Review of existing literature on thrombolytic therapy and adjuvant treatments for acute MI.
- Analysis of the evidence for antiplatelet agents (e.g., aspirin) and antithrombotic agents (e.g., heparin).
- Evaluation of the role of immediate versus elective angioplasty in different patient subsets.
Main Results:
- Thrombolytic therapy effectively reduces mortality and improves left ventricular function in acute MI.
- Aspirin is an established effective adjuvant therapy.
- The utility of other antiplatelet agents and heparin as adjuvant therapy is under investigation.
- Routine immediate angioplasty is not recommended; elective angioplasty is indicated for recurrent ischemia.
- Primary angioplasty may be advantageous in specific situations (cardiogenic shock, contraindications to thrombolysis) but requires further study for broader application.
Conclusions:
- Thrombolytic therapy remains a vital treatment for acute myocardial infarction.
- Aspirin enhances thrombolytic therapy outcomes.
- Further research is needed to clarify the roles of newer antiplatelet agents, heparin, and primary angioplasty in acute MI.
- Angioplasty's practicality is limited by equipment availability compared to thrombolytic therapy.
Abstract:
Thrombolytic therapy markedly reduces mortality and improves left ventricular function in patients with acute myocardial infarction. Improvement may be even more substantial with adjuvant therapy. Aspirin has proved to be effective adjuvant therapy to thrombolysis. Other antiplatelet agents that may be even more effective or have an additive effect with aspirin are being studied. The role of antithrombotic agents, especially heparin, as adjuvant therapy remains unclear. Immediate cardiac catheterization with angioplasty has been used as adjunct therapy, but its routine use is not recommended. Instead, elective angioplasty (cardiac catheterization, with revascularization as indicated) should be undertaken in patients with recurrent ischemia. Angioplasty as an alternative to thrombolysis may be advantageous in certain patients, such as those presenting in cardiogenic shock or with contraindications to thrombolysis. The role of primary angioplasty in other groups (eg, the elderly, those with anterior myocardial infarction) remains unclear, and further trials are necessary before it can be recommended over thrombolytic therapy. Equipment needed for angioplasty limits its practicality, whereas thrombolytic therapy can be administered at most US hospitals.